A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Daratumumab
Related studies linked through entity extraction aliases.
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
- Status
- RECRUITING
- Phase
- PHASE2
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Daratumumab to Treat Active Lupus Nephritis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Daratumumab and Belatacept for Desensitization
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
DARA RVD For High Risk SMM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2